Autolus Therapeutics (NASDAQ:AUTL) Upgraded to “Strong-Buy” at Truist Financial

Autolus Therapeutics (NASDAQ:AUTL) was upgraded by analysts at Truist Financial to a “strong-buy” rating in a research note issued on Wednesday,Zacks.com reports.

A number of other research firms also recently weighed in on AUTL. HC Wainwright began coverage on Autolus Therapeutics in a report on Tuesday, February 17th. They issued a “buy” rating and a $9.00 price objective for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Autolus Therapeutics in a research report on Wednesday, January 21st. Needham & Company LLC decreased their price target on Autolus Therapeutics from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Monday, January 12th. Finally, Zacks Research upgraded Autolus Therapeutics from a “strong sell” rating to a “hold” rating in a research report on Friday, March 13th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $8.50.

Autolus Therapeutics Stock Performance

AUTL stock opened at $1.33 on Wednesday. The company has a market capitalization of $353.97 million, a P/E ratio of -1.60 and a beta of 1.95. The company has a fifty day moving average price of $1.49 and a 200-day moving average price of $1.52. Autolus Therapeutics has a 52-week low of $1.11 and a 52-week high of $2.70.

Hedge Funds Weigh In On Autolus Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Independent Advisor Alliance acquired a new position in Autolus Therapeutics in the fourth quarter valued at $28,000. Marex Group plc acquired a new stake in Autolus Therapeutics during the 2nd quarter worth about $28,000. SmartHarvest Portfolios LLC bought a new position in shares of Autolus Therapeutics in the 4th quarter worth about $43,000. Caitong International Asset Management Co. Ltd bought a new position in shares of Autolus Therapeutics in the 3rd quarter worth about $46,000. Finally, R Squared Ltd lifted its stake in shares of Autolus Therapeutics by 40.1% in the 3rd quarter. R Squared Ltd now owns 30,476 shares of the company’s stock valued at $50,000 after purchasing an additional 8,730 shares during the period. Institutional investors and hedge funds own 72.83% of the company’s stock.

About Autolus Therapeutics

Autolus Therapeutics is a clinical-stage biopharmaceutical company specializing in the development of next-generation, programmed T cell therapies for the treatment of cancer. The company leverages proprietary technologies to engineer autologous T cells that target and eradicate tumor cells, with the aim of improving safety, efficacy and durability over existing cell therapies. Its R&D platform integrates antigen receptor design, gene editing and manufacturing optimization to generate candidates tailored for specific hematologic malignancies and solid tumor indications.

The company’s leading pipeline candidates include AUTO1, an optimized CD19-targeted CAR-T therapy for relapsed or refractory acute lymphoblastic leukemia, and AUTO3, a dual-targeted CD19/22 CAR-T program in development for diffuse large B-cell lymphoma.